# OnCo record kir2dl1 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/kir2dl1/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "kir2dl1" ;
  schema:name "KIR2DL1 (inhibitory KIR)"@en ;
  schema:alternateName "KIR"@en, "CD158a"@en, "p58.1"@en, "KIR2DL2"@en, "KIR2DL3"@en, "CD158b"@en, "KIR2DL1" ;
  schema:description "Inhibitory KIRs are the receptors NK cells use to recognise a person's own HLA-C and stand down. Lirilumab, an antibody that blocks three of them, reached phase 2 but was dropped for blood cancers."@en ;
  schema:url <https://onco.cc/targets/kir2dl1/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6329>, <https://www.uniprot.org/uniprotkb/P43626/entry>, <https://www.ncbi.nlm.nih.gov/gene/3802>, <https://clinicaltrials.gov/study/NCT02599649> ;
  onco:tag "checkpoint-map" ;
  onco:targetClass "checkpoint" ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6329>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125498>, <https://www.uniprot.org/uniprotkb/P43626/entry>, <https://www.ncbi.nlm.nih.gov/gene/3802> ;
  onco:related <https://onco.cc/targets/klrc1/>, <https://onco.cc/terms/nk-cell/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:cancers <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:pathways <https://onco.cc/pathways/cancer-immunity-cycle/> .